According to a literature survey, Worldwide, bladder cancer accounted for 425,750 cases and more than154,500 deaths in 2016. With respect to the staging system that non?muscle?invasive bladder cancer accounted for 70% to 75% of cases with the remaining 20% to 25?ing muscle?invasive disease. With a high risk of recurrence after transurethral resection of an initial tumor; the 1-yr recurrence rate is 15 to 61%, and the 5-yr recurrence rate is 31 to 78%. According to Thelansis Research, Nonmuscle-invasive bladder cancer (NMIBC) accounts for about 60% to 75% of all bladder cancer and is associated with more than 80% survival rate over 5 years. However, up to 70% of NMIBC repeat after initial treatment, of which 10% to 20?n progress to MIBC
Comprehensive insight on patient segmentation based on age, sex, Stage (Ta, Tis & T1 lesions), Grade (Grade I, II & III), Biomarkers (FGFR, P53, Ki-67, CK20, etc.), recurrence & Frequency, Signs & Symptoms, Clinical Manifestations, Treatment types and lines of therapy (Cystoscopic transurethral resection of the bladder tumor, Intravesical Therapy, & Surgery) has been provided into the epidemiology section of the NMIBC and its treatment in the 8 MM coun-tries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies such as CG Oncology, Inc., BioCis Pharma Ltd, Hamlet Pharma AB, Altor BioScience, Aadi, LLC, ImmunityBio, Inc., Pfizer, Ferring Pharmaceuticals, AstraZeneca, Vaxiion Therapeutics, ImmunityBio, Inc., MSD, Bioniche Life Sciences Inc., Uro-Gen Pharma Ltd., BMS, UroGen Pharma Ltd., Spectrum Pharma-ceuticals, Inc, Telormedix SA, Handok Inc., and Photocure are building their assets targeting the NMIBC market
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Dystonia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
clientsupport@thelansis.com
m.berg@thelansis.com
Contact Information:
m.berg@thelansis.com
Tags:
Menafn, PR-Wirein, Reportedtimes, iCN Internal Distribution, Research Newswire, English